Overview

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of high-dose cytarabine plus idarubicin in treating patients with newly diagnosed acute or chronic myelogenous leukemia or myelodysplastic syndrome.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cytarabine
Etoposide
Idarubicin
Lintuzumab
Criteria
DISEASE CHARACTERISTICS: One of the following hematologic malignancies that is ineligible
for higher priority protocols and confirmed at Memorial Hospital: Acute myelogenous
leukemia Accelerated or blastic phase (greater than 10% blasts in marrow) chronic
myelogenous leukemia Poor-risk myelodysplastic syndrome, defined as: Refractory anemia with
excess blasts (RAEB) with at least 10% marrow blasts and cytopenia requiring therapy RAEB
in transformation Chronic myelomonocytic leukemia No acute promyelocytic leukemia

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:
Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL Transaminases no greater than 3
times normal Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance greater
than 60 mL/min Cardiovascular: No cardiomyopathy No symptomatic congestive heart failure
Other: No concurrent active malignancy No pregnant or nursing women

PRIOR CONCURRENT THERAPY: No prior therapy except biologic agent alone or hydroxyurea